ALK and non-small cell lung carcinoma: Phase 3 study of crizotinib in previously treated patients with ALK-rearranged advanced NSCLC showed an ORR of 65% and a PFS of 7.7 months, which was significantly superior to the results with standard chemotherapy [8].